Life Science Nation

A venture capital firm based in Western Europe is currently investing out of their first fund and looks to invest in early-stage life science companies in the therapeutics space. The firm focuses on Seed investments in the form of equity. Typical allocation is up to $5M for the first ticket. Forty51 Ventures invests in European companies but is open to global opportunities....

Hot Investor Mandate: VC Firm With Inaugural Fund Seeks Therapeutics Companies in Oncology, CNS, Rare Diseases, and More With a Focus in Western Europe A venture capital firm based in Western Europe is currently investing out of their first fund and looks to invest in early-stage life science companies in the therapeutics space. The firm focuses o…

A healthcare and life sciences focused venture capital firm with USA and China offices has managed $600 million USD in total assets, including both USD and RMB funds. The firm has invested in over 50 companies with 10 successful IPO and acquisitions. The firm seeks Series A to Series B opportunities in healthcare and life sciences. Typical check size ranges from $5-15 million USD....

Hot Investor Mandate: Investment Firm Allocates Up to $15M in Global Life Science Opportunities, With a Focus on US and China-Based Opportunities A healthcare and life sciences focused venture capital firm with USA and China offices has managed $600 million USD in total assets, including both USD and RMB funds. The firm has invested in over …

A venture capital firm based in the US is currently allocating capital from its third fund, investing between $1-2M in pre-seed and seed-stage companies, targeting approximately 10% as their ownership target. The fund is ~75% deployed and expects to make several more investments over the upcoming quarters. The firm will consider opportunities in the United States and Canada. Within healthcare and life science, the firm is interested in AI-based, non-consumer healthcare IT products....

Hot Investor Mandate: USA-Based VC Invests in Seed-Stage Healthcare IT and AI-Based Life Sciences Companies, Prefers to Lead Rounds A venture capital firm based in the US is currently allocating capital from its third fund, investing between $1-2M in pre-seed and seed-stage companies, targeting approximately 10% as their owners…

A life science venture capital firm with strong China expertise and global capabilities discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. They operate offices in US and China. The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services....

Hot Investor Mandate: Life Science VC with Strong China Market Expertise Seeks Novel Therapeutics Across All Modalities from Seed to Growth Stage A life science venture capital firm with strong China expertise and global capabilities discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. T…

A venture capital firm in the US invests in cancer-focused data accessibility and scalability, infrastructure, education and access, and IT and service start-ups as they look to fundamentally change the way cancer care is designed and delivered at scale. Drugs, therapeutics, or medical devices are not of interest. The firm will invest in Seed stage companies that are currently selling in the market....

Hot Investor Mandate: USA-Based VC Invests in Cancer-Focused Digital Health Technologies, Typically Investing in Seed Opportunities A venture capital firm in the US invests in cancer-focused data accessibility and scalability, infrastructure, education and access, and IT and service start-ups as they look to fundamentally chang…